Sleep Apnea - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Sleep Apnea - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Sleep Apnea - Pipeline Review, H2 2016', provides an overview of the Sleep Apnea pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Sleep Apnea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sleep Apnea and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sleep Apnea
- The report reviews pipeline therapeutics for Sleep Apnea by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Sleep Apnea therapeutics and enlists all their major and minor projects
- The report assesses Sleep Apnea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Sleep Apnea

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Sleep Apnea
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sleep Apnea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Sleep Apnea Overview 6
Therapeutics Development 7
Pipeline Products for Sleep Apnea - Overview 7
Pipeline Products for Sleep Apnea - Comparative Analysis 8
Sleep Apnea - Therapeutics under Development by Companies 9
Sleep Apnea - Therapeutics under Investigation by Universities/Institutes 10
Sleep Apnea - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Sleep Apnea - Products under Development by Companies 14
Sleep Apnea - Products under Investigation by Universities/Institutes 15
Sleep Apnea - Companies Involved in Therapeutics Development 16
Galleon Pharmaceuticals 16
RespireRx Pharmaceuticals Inc. 17
SK Biopharmaceuticals Co., Ltd. 18
Vivus, Inc. 19
Sleep Apnea - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 27
Drug Profiles 28
(phentermine + topiramate) ER - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
CX-1739 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
dronabinol - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
GAL-475 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
GAL-475 Backups - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
SKL-N05 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecule for Sleep Apnea - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Sleep Apnea - Dormant Projects 46
Sleep Apnea - Discontinued Products 47
Sleep Apnea - Product Development Milestones 48
Featured News & Press Releases 48
Jun 14, 2016: Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting 48
Feb 29, 2016: RespireRx Pharmaceuticals Announces Removal of FDA Clinical Hold on CX1739 and Initiation of Phase IIA Clinical Trial by March 31, 2016 49
Jun 08, 2015: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110 as a Potential Treatment of EDS Associated with Narcolepsy or with OSA 49
May 14, 2015: VIVUS Announces Scientific Presentations 50
May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders 51
May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders 52
May 15, 2014: VIVUS Announces Qsymia Presentation at the American Association of Clinical Endocrinologists 52
Jul 01, 2013: VIVUS Announces Initial Availability of Qsymia Through Certified Retail Pharmacies 53
Nov 12, 2012: Study Finds Significant Improvements In Patients With Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules 54
Jan 09, 2012: VIVUS Provides Update On Regulatory Status Of Qnexa 55
Nov 03, 2011: FDA Accepts New Drug Application Filing For Qnexa 55
Apr 26, 2011: Cortex Receives US Patent For Lead AMPAKINE Molecule CX1739 56
Feb 02, 2011: Cortex's Ampakine CX1739 Improves Respiratory Parameters In Obstructive Sleep Apnea Patients 56
Jan 07, 2010: VIVUS Announces Positive Results From Phase II Study Of Qnexa In Obstructive Sleep Apnea 57
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60

List of Tables

Number of Products under Development for Sleep Apnea, H2 2016 7
Number of Products under Development for Sleep Apnea - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Sleep Apnea - Pipeline by Galleon Pharmaceuticals, H2 2016 16
Sleep Apnea - Pipeline by RespireRx Pharmaceuticals Inc., H2 2016 17
Sleep Apnea - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 18
Sleep Apnea - Pipeline by Vivus, Inc., H2 2016 19
Assessment by Monotherapy Products, H2 2016 20
Assessment by Combination Products, H2 2016 21
Number of Products by Stage and Target, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 25
Number of Products by Stage and Route of Administration, H2 2016 26
Number of Products by Stage and Molecule Type, H2 2016 27
Sleep Apnea - Dormant Projects, H2 2016 46
Sleep Apnea - Discontinued Products, H2 2016 47